These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 11550964

  • 1. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R, European Leflunomide Study Group.
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [Abstract] [Full Text] [Related]

  • 2. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR, Schattenkirchner M, Sörensen H, Emery P, Deighton C, Rozman B, Breedveld F.
    Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
    Poór G, Strand V, Leflunomide Multinational Study Group.
    Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
    [Abstract] [Full Text] [Related]

  • 5. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A.
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [Abstract] [Full Text] [Related]

  • 6. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G.
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [Abstract] [Full Text] [Related]

  • 7. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B, Leflunomide Rheumatoid Arthritis Investigators Groups.
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [Abstract] [Full Text] [Related]

  • 8. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P.
    Ann Rheum Dis; 2005 Jan; 64(1):44-51. PubMed ID: 15271770
    [Abstract] [Full Text] [Related]

  • 9. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
    Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I, European Leflunomide Study Group.
    Ann Rheum Dis; 2001 Oct; 60(10):913-23. PubMed ID: 11557646
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 11. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
    Goldenberg MM.
    Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S.
    Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
    [Abstract] [Full Text] [Related]

  • 13. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 14. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 15. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL.
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [Abstract] [Full Text] [Related]

  • 16. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F, Michaud K, Stephenson B, Doyle J.
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [Abstract] [Full Text] [Related]

  • 17. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
    Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V.
    Arthritis Rheum; 1999 Jul; 42(7):1322-8. PubMed ID: 10403258
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
    Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P, Treatment of Psoriatic Arthritis Study Group.
    Arthritis Rheum; 2004 Jun; 50(6):1939-50. PubMed ID: 15188371
    [Abstract] [Full Text] [Related]

  • 20. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.